[Pharmacokinetics of clonidine and chlorthalidone following subacute administration of a fixed combination compared with a sustained release formulation of clonidine alone (author's transl)].
Clonidine concentrations in urines and blood plasma samples analysed by RIA were observed over a period of 240 h in 6 male, healthy, normotensive volunteers being treated for 7 days with sustained-release formulations of 2-(2,6-dichloroanilino)-2-imidazoline (clonidine, Catapresan) alone (0.15 mg/d) and subsequently with a combination containing 0.15 mg clonidine plus 15 mg chlorthalidone. Chlorthalidone was determined in blood samples using a newly developed massfragmentographic method. The trials revealed: 1. There is no influence of chlorthalidone on the pharmacokinetics of clonidine. 2. the steady-state levels of the plasma or blood concentrations being reached on the 2nd (clonidine) and on the 5th day (chlorthalidone) were adjusted subsequently in therapeutically relevant ranges ranging between minima and maxima of 0.2 and 0.6 ng/ml (clonidine) and between 2.4 and 2.6 microgram/ml (chlorthalidone) respectively. From pharmacokinetic aspects therefore a fixed combination of two synergistic antihypertensive agents can be considered as useful. 3. Following 7 administrations of either clonidine formulation 63% of the total clonidine doses were excreted renally.
D000328:Adult; D002752:Chlorthalidone / Q000008:administration & dosage / Q000378:metabolism*; D003000:Clonidine / Q000008:administration & dosage / Q000378:metabolism*; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D003000:Clonidine; D002752:Chlorthalidone
Pharmakokinetiken von Clonidin und Chlorthalidon nach subakuter Gabe eines fixen Kombinationspräparates im Vergleich zu Clonidin als Monretardpräparat.